Lactobacillus casei Shirota Supplementation Does Not Restore Gut Microbiota Composition and Gut Barrier in Metabolic Syndrome: A Randomized Pilot Study

Vanessa Stadlbauer, Bettina Leber, Sandra Lemesch, Slave Trajanoski, Mina Bashir, Angela Horvath, Monika Tawdrous, Tatjana Stojakovic, Günter Fauler, Peter Fickert, Christoph Högenauer, Ingeborg Klymiuk, Philipp Stiegler, Manfred Lamprecht, Thomas R Pieber, Norbert J Tripolt, Harald Sourij, Vanessa Stadlbauer, Bettina Leber, Sandra Lemesch, Slave Trajanoski, Mina Bashir, Angela Horvath, Monika Tawdrous, Tatjana Stojakovic, Günter Fauler, Peter Fickert, Christoph Högenauer, Ingeborg Klymiuk, Philipp Stiegler, Manfred Lamprecht, Thomas R Pieber, Norbert J Tripolt, Harald Sourij

Abstract

Metabolic syndrome is associated with disturbances in gut microbiota composition. We aimed to investigate the effect of Lactobacillus casei Shirota (LcS) on gut microbiota composition, gut barrier integrity, intestinal inflammation and serum bile acid profile in metabolic syndrome. In a single-centre, prospective, randomised controlled pilot study, 28 subjects with metabolic syndrome received either LcS for 12 weeks (n = 13) or no LcS (n = 15). Data were compared to healthy controls (n = 16). Gut microbiota composition was characterised from stool using 454 pyrosequencing of 16S rRNA genes. Serum bile acids were quantified by tandem mass spectrometry. Zonulin and calprotectin were measured in serum and stool by ELISA. Bacteroidetes/Firmicutes ratio was significantly higher in healthy controls compared to metabolic syndrome but was not influenced by LcS. LcS supplementation led to enrichment of Parabacteroides. Zonulin and calprotectin were increased in metabolic syndrome stool samples but not influenced by LcS supplementation. Serum bile acids were similar to controls and not influenced by LcS supplementation. Metabolic syndrome is associated with a higher Bacteroidetes/Firmicutes ratio and gut barrier dysfunction but LcS was not able to change this. LcS administration was associated with subtle microbiota changes at genus level.

Trial registration: ClinicalTrials.gov NCT01182844.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. Flow diagram of the study…
Fig 1. Flow diagram of the study progress.
Fig 2. Gut microbiota composition in MetS…
Fig 2. Gut microbiota composition in MetS patients and controls.
Bacteroidetes/Firmicutes ratio (a) PCoA Plot (Weighted UniFrac, b) and abundance of Parabacteroides (c) concerning LcS supplementation.

References

    1. WHO. Obesity and overweight. Fact sheet. 2014;131.
    1. Thomas GN, Schooling CM, McGhee SM, Ho SY, Cheung BM, Wat NM, et al. Metabolic syndrome increases all-cause and vascular mortality: the Hong Kong Cardiovascular Risk Factor Study. Clinical endocrinology. 2007;66(5):666–71. 10.1111/j.1365-2265.2007.02798.x .
    1. Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083–96. 10.1016/S0140-6736(09)60318-4
    1. Esteve E, Ricart W, Fernandez-Real JM. Gut microbiota interactions with obesity, insulin resistance and type 2 diabetes: did gut microbiote co-evolve with insulin resistance? Current opinion in clinical nutrition and metabolic care. 2011;14(5):483–90. 10.1097/MCO.0b013e328348c06d .
    1. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005;102(31):11070–5. .
    1. Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science. 2005;307(5717):1915–20. .
    1. Duncan SH, Lobley GE, Holtrop G, Ince J, Johnstone AM, Louis P, et al. Human colonic microbiota associated with diet, obesity and weight loss. Int J Obes (Lond). 2008;32(11):1720–4. Epub 2008/09/10. 10.1038/ijo.2008.155 ijo2008155 [pii]. .
    1. Schwiertz A, Taras D, Schafer K, Beijer S, Bos NA, Donus C, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring). 2010;18(1):190–5. Epub 2009/06/06. 10.1038/oby.2009.167 oby2009167 [pii]. .
    1. Zupancic ML, Cantarel BL, Liu Z, Drabek EF, Ryan KA, Cirimotich S, et al. Analysis of the gut microbiota in the old order Amish and its relation to the metabolic syndrome. PLoS One. 2012;7(8):e43052 Epub 2012/08/21. 10.1371/journal.pone.0043052 PONE-D-11-23689 [pii].
    1. Zhang H, DiBaise JK, Zuccolo A, Kudrna D, Braidotti M, Yu Y, et al. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A. 2009;106(7):2365–70. Epub 2009/01/24. 10.1073/pnas.0812600106 0812600106 [pii].
    1. Creely SJ, McTernan PG, Kusminski CM, Fisher M, Da Silva NF, Khanolkar M, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. American journal of physiologyEndocrinology and metabolism. 2007;292(3):E740–7. 10.1152/ajpendo.00302.2006
    1. Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 2010;5(2):e9085 10.1371/journal.pone.0009085
    1. Stenman LK, Holma R, Eggert A, Korpela R. A novel mechanism for gut barrier dysfunction by dietary fat: epithelial disruption by hydrophobic bile acids. Am J Physiol Gastrointest Liver Physiol. 2013;304(3):G227–34. Epub 2012/12/04. 10.1152/ajpgi.00267.2012 ajpgi.00267.2012 [pii]. .
    1. Stenman LK, Holma R, Korpela R. High-fat-induced intestinal permeability dysfunction associated with altered fecal bile acids. World J Gastroenterol. 2012;18(9):923–9. Epub 2012/03/13. 10.3748/wjg.v18.i9.923
    1. Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Current pharmaceutical design. 2009;15(13):1546–58. .
    1. Cani PD, Delzenne NM. Interplay between obesity and associated metabolic disorders: new insights into the gut microbiota. Current opinion in pharmacology. 2009;9(6):737–43. 10.1016/j.coph.2009.06.016 .
    1. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57(6):1470–81. 10.2337/db07-1403
    1. Naito E, Yoshida Y, Makino K, Kounoshi Y, Kunihiro S, Takahashi R, et al. Beneficial effect of oral administration of Lactobacillus casei strain Shirota on insulin resistance in diet-induced obesity mice. J Appl Microbiol. 2011;110(3):650–7. 10.1111/j.1365-2672.2010.04922.x
    1. Andreasen AS, Larsen N, Pedersen-Skovsgaard T, Berg RM, Moller K, Svendsen KD, et al. Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. Br J Nutr. 2010;104(12):1831–8. 10.1017/S0007114510002874 .
    1. Leber B, Tripolt NJ, Blattl D, Eder M, Wascher TC, Pieber TR, et al. The influence of probiotic supplementation on gut permeability in patients with metabolic syndrome: an open label, randomized pilot study. Eur J Clin Nutr. 2012;66(10):1110–5. 10.1038/ejcn.2012.103 .
    1. Tripolt NJ, Leber B, Blattl D, Eder M, Wonisch W, Scharnagl H, et al. Short communication: Effect of supplementation with Lactobacillus casei Shirota on insulin sensitivity, beta-cell function, and markers of endothelial function and inflammation in subjects with metabolic syndrome-A pilot study. J Dairy Sci. 2012. Epub 2012/11/21. S0022-0302(12)00847-8 [pii] 10.3168/jds.2012-5863 .
    1. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5. 10.1161/circulationaha.109.192644
    1. Baker GC, Smith JJ, Cowan DA. Review and re-analysis of domain-specific 16S primers. J Microbiol Methods. 2003;55(3):541–55. .
    1. Watanabe K, Kodama Y, Harayama S. Design and evaluation of PCR primers to amplify bacterial 16S ribosomal DNA fragments used for community fingerprinting. J Microbiol Methods. 2001;44(3):253–62. .
    1. Kump PK, Grochenig HP, Lackner S, Trajanoski S, Reicht G, Hoffmann KM, et al. Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflammatory bowel diseases. 2013;19(10):2155–65. 10.1097/MIB.0b013e31829ea325 .
    1. Stojakovic T, Putz-Bankuti C, Fauler G, Scharnagl H, Wagner M, Stadlbauer V, et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology. 2007;46(3):776–84. Epub 2007/08/03. 10.1002/hep.21741 .
    1. Huse SM, Welch DM, Morrison HG, Sogin ML. Ironing out the wrinkles in the rare biosphere through improved OTU clustering. Environ Microbiol. 2010;12(7):1889–98. 10.1111/j.1462-2920.2010.02193.x
    1. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, et al. QIIME allows analysis of high-throughput community sequencing data. Nature methods. 2010;7(5):335–6. 10.1038/nmeth.f.303
    1. Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics. 2010;26(19):2460–1. 10.1093/bioinformatics/btq461 .
    1. Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol. 2007;73(16):5261–7. 10.1128/AEM.00062-07
    1. McDonald D, Price MN, Goodrich J, Nawrocki EP, DeSantis TZ, Probst A, et al. An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. ISME J. 2012;6(3):610–8. 10.1038/ismej.2011.139
    1. Caporaso JG, Bittinger K, Bushman FD, DeSantis TZ, Andersen GL, Knight R. PyNAST: a flexible tool for aligning sequences to a template alignment. Bioinformatics. 2010;26(2):266–7. 10.1093/bioinformatics/btp636
    1. Haas BJ, Gevers D, Earl AM, Feldgarden M, Ward DV, Giannoukos G, et al. Chimeric 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons. Genome research. 2011;21(3):494–504. 10.1101/gr.112730.110
    1. Price MN, Dehal PS, Arkin AP. FastTree 2—approximately maximum-likelihood trees for large alignments. PLoS One. 2010;5(3):e9490 10.1371/journal.pone.0009490
    1. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A. 2007;104(3):979–84. 10.1073/pnas.0605374104
    1. Ley RE. Obesity and the human microbiome. Current opinion in gastroenterology. 2010;26(1):5–11. 10.1097/MOG.0b013e328333d751
    1. Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. The Journal of clinical investigation. 2011;121(6):2126–32. doi:
    1. Tremaroli V, Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012;489(7415):242–9. 10.1038/nature11552 .
    1. Parekh PJ, Arusi E, Vinik AI, Johnson DA. The Role and Influence of Gut Microbiota in Pathogenesis and Management of Obesity and Metabolic Syndrome. Front Endocrinol (Lausanne). 2014;5:47 Epub 2014/04/30. 10.3389/fendo.2014.00047 .
    1. Roager HM, Licht TR, Poulsen SK, Larsen TM, Bahl MI. Microbial enterotypes, inferred by the prevotella-to-bacteroides ratio, remained stable during a 6-month randomized controlled diet intervention with the new nordic diet. Appl Environ Microbiol. 2014;80(3):1142–9. 10.1128/AEM.03549-13
    1. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55–60. 10.1038/nature11450 .
    1. Fukuda S, Ohno H. Gut microbiome and metabolic diseases. Seminars in immunopathology. 2014;36(1):103–14. 10.1007/s00281-013-0399-z .
    1. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005;102(31):11070–5. 10.1073/pnas.0504978102
    1. Martinez I, Kim J, Duffy PR, Schlegel VL, Walter J. Resistant starches types 2 and 4 have differential effects on the composition of the fecal microbiota in human subjects. PLoS One. 2010;5(11):e15046 10.1371/journal.pone.0015046
    1. De Cruz P, Kang S, Wagner J, Buckley M, Sim WH, Prideaux L, et al. Specific Mucosa-Associated Microbiota in Crohn's Disease at the Time of Resection are Associated with Early Disease Recurrence: A Pilot Study. Journal of gastroenterology and hepatology. 2014. 10.1111/jgh.12694
    1. Wong VW, Tse CH, Lam TT, Wong GL, Chim AM, Chu WC, et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis—a longitudinal study. PLoS One. 2013;8(4):e62885 10.1371/journal.pone.0062885
    1. Shirota M, Aso K, Iwabuchi A. Studies on intestinal microflora. 1. Its constitution in healthy infants and the effect of oral administration of L. acidophilus strain Shirota. Nippon saikingaku zasshiJapanese journal of bacteriology. 1966;21(5):274–83.
    1. Spanhaak S, Havenaar R, Schaafsma G. The effect of consumption of milk fermented by Lactobacillus casei strain Shirota on the intestinal microflora and immune parameters in humans. Eur J Clin Nutr. 1998;52(12):899–907.
    1. Tuohy KM, Pinart-Gilberga M, Jones M, Hoyles L, McCartney AL, Gibson GR. Survivability of a probiotic Lactobacillus casei in the gastrointestinal tract of healthy human volunteers and its impact on the faecal microflora. J Appl Microbiol. 2007;102(4):1026–32. 10.1111/j.1365-2672.2006.03154.x
    1. Takeda K, Okumura K. Effects of a fermented milk drink containing Lactobacillus casei strain Shirota on the human NK-cell activity. The Journal of nutrition. 2007;137(3 Suppl 2):791S–3S.
    1. Stadlbauer V, Mookerjee RP, Hodges S, Wright GA, Davies NA, Jalan R. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol. 2008;48(6):945–51. 10.1016/j.jhep.2008.02.015
    1. Tiengrim S, Leelaporn A, Manatsathit S, Thamlikitkul V. Viability of Lactobacillus casei strain Shirota (LcS) from feces of Thai healthy subjects regularly taking milk product containing LcS. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 2012;95 Suppl 2:S42–7. Epub 2012/05/12. .
    1. Yuki N, Watanabe K, Mike A, Tagami Y, Tanaka R, Ohwaki M, et al. Survival of a probiotic, Lactobacillus casei strain Shirota, in the gastrointestinal tract: selective isolation from faeces and identification using monoclonal antibodies. International journal of food microbiology. 1999;48(1):51–7. Epub 1999/06/22. .
    1. Fujimoto J, Matsuki T, Sasamoto M, Tomii Y, Watanabe K. Identification and quantification of Lactobacillus casei strain Shirota in human feces with strain-specific primers derived from randomly amplified polymorphic DNA. International journal of food microbiology. 2008;126(1–2):210–5. 10.1016/j.ijfoodmicro.2008.05.022 .
    1. Sakai T, Oishi K, Asahara T, Takada T, Yuki N, Matsumoto K, et al. M-RTLV agar, a novel selective medium to distinguish Lactobacillus casei and Lactobacillus paracasei from Lactobacillus rhamnosus. International journal of food microbiology. 2010;139(3):154–60. 10.1016/j.ijfoodmicro.2010.03.019 .
    1. Tilley L, Keppens K, Kushiro A, Takada T, Sakai T, Vaneechoutte M, et al. A probiotic fermented milk drink containing Lactobacillus cassei strain Shirota improves stool consistency of subjects with hard stools. International Journal of Probiotics and Prebiotics. 2014;9(1–2):23–30.
    1. Fasano A. Regulation of intercellular tight junctions by zonula occludens toxin and its eukaryotic analogue zonulin. Ann N Y Acad Sci. 2000;915:214–22. Epub 2001/02/24. .
    1. Wang W, Uzzau S, Goldblum SE, Fasano A. Human zonulin, a potential modulator of intestinal tight junctions. J Cell Sci. 2000;113 Pt 24:4435–40. Epub 2000/11/18. .
    1. Fasano A, Not T, Wang W, Uzzau S, Berti I, Tommasini A, et al. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet. 2000;355(9214):1518–9. Epub 2000/05/09. S0140-6736(00)02169-3 [pii] 10.1016/S0140-6736(00)02169-3 .
    1. Moreno-Navarrete JM, Sabater M, Ortega F, Ricart W, Fernandez-Real JM. Circulating zonulin, a marker of intestinal permeability, is increased in association with obesity-associated insulin resistance. PLoS One. 2012;7(5):e37160 Epub 2012/05/26. 10.1371/journal.pone.0037160 PONE-D-12-01867 [pii].
    1. Goodrich KM, Fundaro G, Griffin LE, Grant A, Hulver MW, Ponder MA, et al. Chronic administration of dietary grape seed extract increases colonic expression of gut tight junction protein occludin and reduces fecal calprotectin: a secondary analysis of healthy Wistar Furth rats. Nutr Res. 2012;32(10):787–94. Epub 2012/11/14. 10.1016/j.nutres.2012.09.004 S0271-5317(12)00186-8 [pii]. .
    1. Vulevic J, Juric A, Tzortzis G, Gibson GR. A mixture of trans-galactooligosaccharides reduces markers of metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults. J Nutr. 2013;143(3):324–31. Epub 2013/01/11. 10.3945/jn.112.166132 jn.112.166132 [pii]. .
    1. Raimondi F, Santoro P, Barone MV, Pappacoda S, Barretta ML, Nanayakkara M, et al. Bile acids modulate tight junction structure and barrier function of Caco-2 monolayers via EGFR activation. Am J Physiol Gastrointest Liver Physiol. 2008;294(4):G906–13. Epub 2008/02/02. 10.1152/ajpgi.00043.2007 .
    1. Stenman LK, Holma R, Gylling H, Korpela R. Genetically obese mice do not show increased gut permeability or faecal bile acid hydrophobicity. Br J Nutr. 2013;110(6):1157–64. Epub 2013/02/28. 10.1017/S000711451300024X .
    1. Liaset B, Hao Q, Jorgensen H, Hallenborg P, Du ZY, Ma T, et al. Nutritional regulation of bile acid metabolism is associated with improved pathological characteristics of the metabolic syndrome. The Journal of biological chemistry. 2011;286(32):28382–95. Epub 2011/06/18. 10.1074/jbc.M111.234732
    1. Watanabe M, Horai Y, Houten SM, Morimoto K, Sugizaki T, Arita E, et al. Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. The Journal of biological chemistry. 2011;286(30):26913–20. Epub 2011/06/03. 10.1074/jbc.M111.248203
    1. Steiner C, Othman A, Saely CH, Rein P, Drexel H, von Eckardstein A, et al. Bile acid metabolites in serum: intraindividual variation and associations with coronary heart disease, metabolic syndrome and diabetes mellitus. PLoS One. 2011;6(11):e25006 Epub 2011/11/24. 10.1371/journal.pone.0025006
    1. Voreades N, Kozil A, Weir TL. Diet and the development of the human intestinal microbiome. Frontiers in microbiology. 2014;5:494 10.3389/fmicb.2014.00494
    1. Mariat D, Firmesse O, Levenez F, Guimaraes V, Sokol H, Dore J, et al. The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol. 2009;9:123 10.1186/1471-2180-9-123

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다